Compare Ascendis Pharma A/S (ASND) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Star Bulk Carriers Corp — how do they compare? Ascendis Pharma A/S trades at $263.66 (market cap $17.74B), while Star Bulk Carriers Corp trades at $26.6 (market cap $2.94B). The key difference: Ascendis Pharma A/S is far larger — about 6× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays a 3.91% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | SBLK | |
|---|---|---|
Market Cap | $17.74B | $2.94B |
Sector | Health | Industrials |
52-Week High | $277.18 | $28.21 |
52-Week Low | $163.32 | $16.79 |
Enterprise Value | $18.11B | $3.64B |
Dividend Yield | — | 3.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Star Bulk Carriers (SBLK) trades at $26.35, up 1.82% today, with a neutral technical signal and bullish moving averages. The company reported strong Q1 2026 earnings of $0.56 per share, beating estimates, and maintains a dividend payout. Revenue grew to $1.1 billion in 2026, with net income margin improving to 13.01%. Analyst consensus is bullish with 14 buy ratings.
SBLK presents a positive outlook with earnings beats and dividend returns, but faces risks from dry bulk market volatility and economic cycles. The stock's valuation at a P/E of 21.08 is reasonable given growth, yet investor caution is warranted on global trade fluctuations impacting shipping demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
